ANDA 220119, held by Biocon Pharma Limited. Carbidopa,Levodopa.
As of Nov 16, 2026, ANDA 220119 (Carbidopa And Levodopa), held by Biocon Pharma Limited, was not approved, with 0 approved supplements and 0 published complete response letters.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Aug 3, 2026 | Original application | Tentative approval | None posted |
| Carbidopa And Levodopa145MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa23.75MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa95MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa245MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa61.25MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa48.75MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
| Carbidopa And Levodopa195MG · capsule, extended release | Carbidopa,Levodopa | None (tentative approval) |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters